NurExone Joins Boston Life Sciences Gatherings Ahead of ExoPTEN IND Efforts
NurExone Biologic Inc. (NRX.V), a biotechnology firm championing exosome‑based regenerative therapies, announced participation in four life‑sciences events in Boston scheduled for September 22‑25, 2026.
The upcoming portfolio includes the 8th Exosome‑Based Therapeutics Development Summit, the LSX Congress USA (2026), BioProcess International, and the World Medical Innovation Forum.
NurExone specializes in exosome‑based regenerative approaches targeting central nervous system injuries. Its lead candidate, ExoPTEN, is currently advancing through preclinical development as a treatment for acute spinal cord injury.
Company reports indicate that preclinical investigations of ExoPTEN have produced promising efficacy data in acute spinal cord injury and optic nerve damage models.
The firm’s latest quarterly results highlighted ongoing efforts to prepare a potential IND application for ExoPTEN during the first half of 2027.
For the second quarter ending June 30, 2026, the company’s net loss narrowed to $1.68 million from $1.85 million a year earlier.
Attending these conferences could provide valuable exposure for the company’s development pipeline to investors, researchers, manufacturers, and members of the healthcare sector.
Over the past twelve months, NRX.V has quoted between C$0.43 and C$1.12; the stock closed Friday at C$0.600, down 13.04 %.